These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36305769)

  • 1. kinCSM: Using graph-based signatures to predict small molecule CDK2 inhibitors.
    Zhou Y; Al-Jarf R; Alavi A; Nguyen TB; Rodrigues CHM; Pires DEV; Ascher DB
    Protein Sci; 2022 Nov; 31(11):e4453. PubMed ID: 36305769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
    Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
    Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
    Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-guided machine learning prediction of drug resistance mutations in Abelson 1 kinase.
    Zhou Y; Portelli S; Pat M; Rodrigues CHM; Nguyen TB; Pires DEV; Ascher DB
    Comput Struct Biotechnol J; 2021; 19():5381-5391. PubMed ID: 34667533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cropCSM: designing safe and potent herbicides with graph-based signatures.
    Pires DEV; Stubbs KA; Mylne JS; Ascher DB
    Brief Bioinform; 2022 Mar; 23(2):. PubMed ID: 35211724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supervised machine learning techniques to predict binding affinity. A study for cyclin-dependent kinase 2.
    de Ávila MB; Xavier MM; Pintro VO; de Azevedo WF
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):305-310. PubMed ID: 29017921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review.
    Volkart PA; Bitencourt-Ferreira G; Souto AA; de Azevedo WF
    Curr Drug Targets; 2019; 20(7):716-726. PubMed ID: 30516105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
    Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
    Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
    Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
    Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. piscesCSM: prediction of anticancer synergistic drug combinations.
    AlJarf R; Rodrigues CHM; Myung Y; Pires DEV; Ascher DB
    J Cheminform; 2024 Jul; 16(1):81. PubMed ID: 39030592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pdCSM-PPI: Using Graph-Based Signatures to Identify Protein-Protein Interaction Inhibitors.
    Rodrigues CHM; Pires DEV; Ascher DB
    J Chem Inf Model; 2021 Nov; 61(11):5438-5445. PubMed ID: 34719929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
    Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors.
    Duca JS
    Future Med Chem; 2009 Nov; 1(8):1453-66. PubMed ID: 21426059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
    El-Naggar AM; El-Hashash MA; Elkaeed EB
    Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, antineoplastic activity of new pyrazolo[3,4-d]pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME prediction.
    Nemr MTM; Elshewy A; Ibrahim ML; El Kerdawy AM; Halim PA
    Bioorg Chem; 2024 Sep; 150():107566. PubMed ID: 38896936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Machine Learning Techniques to Predict Binding Affinity for Drug Targets: A Study of Cyclin-Dependent Kinase 2.
    Bitencourt-Ferreira G; Duarte da Silva A; Filgueira de Azevedo W
    Curr Med Chem; 2021; 28(2):253-265. PubMed ID: 31729287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards more accurate pharmacophore modeling: Multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2.
    Zou J; Xie HZ; Yang SY; Chen JJ; Ren JX; Wei YQ
    J Mol Graph Model; 2008 Nov; 27(4):430-8. PubMed ID: 18786843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational Prediction of Binding Affinity for CDK2-ligand Complexes. A Protein Target for Cancer Drug Discovery.
    Veit-Acosta M; de Azevedo Junior WF
    Curr Med Chem; 2022; 29(14):2438-2455. PubMed ID: 34365938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.